Hudson River Biotechnology raises €5m Series A funding to accelerate growth of its plant gene editing business and expand into nanoparticles for use in field applications

Ferdinand Los, CSO at Hudson River Biotechnology: “We strongly believe in our ability to keep innovating and be at the forefront of technological developments. This funding is another building block, which will allow us to further scale up the existing gene editing business.” Additionally, HRB will grow its staff count from 25 to 40 in the next 12 months and increase its laboratory space to some 1000 square meters (10600 sq.ft.).

Read the full press release here